<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860661</url>
  </required_header>
  <id_info>
    <org_study_id>EKET</org_study_id>
    <nct_id>NCT04860661</nct_id>
  </id_info>
  <brief_title>Esketamine on Postpartum Depression in Cesarean Section Women</brief_title>
  <acronym>EKET</acronym>
  <official_title>Effect of Prophylactic Esketamine on Postpartum Depression in Cesarean Section: A Multicenter, Prospective, Randomized, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ailin Luo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of University of South China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Women and Children Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalian Municipal Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Jining No.1 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maternal and Child Health Hospital of Hubei Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was to explore the preventive effect of esketamine on postpartum depression in&#xD;
      cesarean section, and to evaluate the safety of the drug&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have shown that esketamine can treat clinical refractory depression, the drug takes&#xD;
      effect quickly, can quickly eliminate the patient's suicide intention, low-dose maintenance&#xD;
      treatment is conducive to the stability of the patient's condition, and less adverse&#xD;
      reactions, is the current hot spot of antidepressant drug research. Esketamine has been&#xD;
      approved by FDA for the treatment of refractory and suicidal depression, but can it&#xD;
      effectively prevent and treat postpartum depression? It is not clear. Based on this, this&#xD;
      study aims to explore the preventive effect of prophylactic administration of esketamine on&#xD;
      postpartum depression in cesarean section, and evaluate the safety of the drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The incidence of PPD: the EPDS scale was assessed by face-to-face or telephone interview of the Puerpera 24 h, 7 d, 30 d, 60 d and 90 d after delivery. EPDS score ≥ 10 was defined as antenatal depression or postpartum emotional disorder.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Assign a researcher to determine the order of patients and coordinate the relationship between researchers;&#xD;
For each patient, an anesthesiologist was assigned to manage anesthesia and collect intraoperative data;&#xD;
A researcher who was not aware of the protocol was assigned to conduct preoperative evaluation and postoperative follow-up, and received training on evaluation methods before the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Edinburgh Postnatal Depression Scale(EPDS） scores</measure>
    <time_frame>up to 90 days after surgery</time_frame>
    <description>EPDS score is 0-30，and ≥ 10 to indicate depression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale/Score (VAS) score</measure>
    <time_frame>1 Day before operation</time_frame>
    <description>VAS score is 0-100，and ≥ 30 to indicate the pain needs treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total number of PCA compressions</measure>
    <time_frame>up to 24 hours after operation</time_frame>
    <description>the total number of PCA compressions which the patients pressed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total volume of PCA</measure>
    <time_frame>up to 24 hours after operation</time_frame>
    <description>the total volume of PCA drugs which the patients needed in 24h after sugery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1248</enrollment>
  <condition>Esketamine</condition>
  <condition>Postpartum Depression</condition>
  <arm_group>
    <arm_group_label>N group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>15 minutes after umbilical cord amputation, the patient was intravenously injected with 10 ml normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Es group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 minutes after umbilical cord amputation, the patient was intravenously injected with 0.25mg/kg esketamine, PCIA regimen: sufentanil 100 μ g, esketamine 80 mg, diluted to 100 ml with 0.9% normal saline, set analgesia pump background infusion dose 2 ml/h, single bolus dose 2 ml, locking time 8 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine</intervention_name>
    <description>After delivery, the parturient was given a loading dose of esketamine, and then a small dose of esketamine was added into PCIA analgesia pump</description>
    <arm_group_label>Es group</arm_group_label>
    <other_name>Es group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>10 ml normal saline</description>
    <arm_group_label>N group</arm_group_label>
    <other_name>Ns group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elective cesarean section;&#xD;
&#xD;
          -  18-40 years;&#xD;
&#xD;
          -  Primipara;&#xD;
&#xD;
          -  Singleton pregnancy;&#xD;
&#xD;
          -  Sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA grade III and above;&#xD;
&#xD;
          -  Intracranial hypertension;&#xD;
&#xD;
          -  Hypertension;&#xD;
&#xD;
          -  Severe heart disease;&#xD;
&#xD;
          -  Hyperthyroidism patients without treatment or insufficient treatment;&#xD;
&#xD;
          -  Liver and kidney dysfunction;&#xD;
&#xD;
          -  Preeclampsia or eclampsia;&#xD;
&#xD;
          -  Mental disorder, mental retardation;&#xD;
&#xD;
          -  Drug abuse and alcoholism;&#xD;
&#xD;
          -  Contraindication of intraspinal anesthesia;&#xD;
&#xD;
          -  The preoperative EPDS score ≥10;&#xD;
&#xD;
          -  Participated in other clinical studies.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The objects of this observation were puerpera with cesarean section</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ailin luo, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology of Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Gao, Dr.</last_name>
    <phone>86-27-83663173</phone>
    <email>fgao@tjh.tjmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>aijun xu, Dr.</last_name>
    <phone>86-27-83663173</phone>
    <email>ajxu@tjh.tjmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>April 25, 2021</last_update_submitted>
  <last_update_submitted_qc>April 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Ailin Luo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression, Postpartum</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

